Published in Clinical Oncology Week, January 9th, 2006
"Gemcitabine plus carboplatin is a widely used regimen for the treatment of advanced NSCLC. This two drug combination is effective, with a favorable safety profile, and is well tolerated in the outpatient setting," scientists in England reported.
"Gemcitabine/carboplatin prolongs survival compared with gemcitabine alone, but with greater hematological toxicity. The combination regimen appears to be superior to or equally effective as other regimens including mitomycin, ifosfamide and cisplatin (MIC), cisplatin/vinblastine, gemcitabine/paclitaxel,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.